Evofem Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine months ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(2,397) | $(5,823) |
| Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash used in operating activities: | ||
| Loss on issuance of financial instruments | - | 3,300 |
| Gain on debt extinguishment | - | (977) |
| Gain on change in accounting estimates on contingent royalty liability | (1,933) | - |
| Change in fair value of financial instruments | 490 | (4,896) |
| Inventory write-down for excess & obsolescence | 178 | - |
| Loss on contingent liability | 25 | 840 |
| Stock-based compensation | 124 | 659 |
| Depreciation | 14 | 25 |
| Amortization of intangible asset | 410 | 301 |
| Noncash interest expense | 1,760 | 1,673 |
| Noncash right-of-use amortization | 95 | 69 |
| Net loss on disposal or impairment of property and equipment | 20 | 11 |
| Gain on accounts payable and accrued expenses settlements | (5,618) | - |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | 5,397 | 345 |
| Inventories | (285) | 234 |
| Prepaid and other assets | 500 | 195 |
| Accounts payable | (1,365) | (211) |
| Accrued expenses and other liabilities | 1,016 | 2,234 |
| Accrued compensation | 115 | 613 |
| Contingent liabilities | (475) | - |
| Operating lease liabilities | (94) | (69) |
| Net cash, cash equivalents and restricted cash used in operating activities | (2,023) | (1,477) |
| Cash flows from investing activities: | ||
| Payments related to asset acquisition | (57) | (509) |
| Purchases of property and equipment | (2) | (14) |
| Net cash, cash equivalents and restricted cash used in investing activities | (59) | (523) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of Aditxt Notes – Related Party | 2,425 | - |
| Borrowings under short-term debt and Notes – carried at fair value | 383 | 397 |
| Proceeds from reinstatement of Merger Agreement – Related Party | - | 1,000 |
| Proceeds from issuance of preferred stock – Related Party | - | 1,260 |
| Payments under short term debt and Notes – carried at fair value | (627) | (515) |
| Net cash, cash equivalents and restricted cash provided by financing activities | 2,181 | 2,142 |
| Net change in cash, cash equivalents and restricted cash | 99 | 142 |
| Cash, cash equivalents and restricted cash, beginning of period | 741 | 580 |
| Cash, cash equivalents and restricted cash, end of period | $840 | $722 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Net increase/(decrease) in contingent liabilities | $(3,950) | $13,743 |
| Exchange of convertible notes to Series G-1 convertible and redeemable preferred stock | 369 | - |
| Addition to ROU asset and lease liability due to new leases | 201 | 90 |
| Purchases of property and equipment included in accounts payable and accrued expenses | 78 | 78 |
| Series E-1 and G-1 Shares deemed dividends | 115 | 99 |
| Issuance of Common Stock upon exercise of purchase rights | 2 | 168 |
| Issuance of Common Stock upon conversion of notes | - | 51 |
| Issuance of Common Stock upon exercise of warrants | - | 15 |
| Allocation of reinstatement proceeds – Related Party | - | 316 |
| Acquisition related amounts included in accounts payable and accrued expenses | - | 70 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.